Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Research Council grant · Running

ALLENEDRUG Targeting Type 2 Diabetes with Allene-containing Molecules Using a C-N Bond Cleavage Tool

Coordinator
Universidad Autonoma De Madrid, Spain
Runs
1 July 2025 to 31 December 2026
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101213797

What the project is doing

In the project's own words, from its summary on CORDIS.

Type 2 Diabetes is a chronic disease affecting more than 450 million people world-wide and is still an unmet medical need. PPAR´s(Peroxisome Proliferator-Activated Receptors) and G-protein-coupled receptors (GPCR) FFARs (Free Fatty Acid Receptors) are wellclinical validated targets for type-2 diabetes. Although selective GPR40 agonists have reached clinical phase III, the trials wererecently terminated due to signs of liver toxicity in patients.

ALLENEDRUG is designed to provide a new chemical series of GPR40ligands aiming to bring a safer type-2 diabetes therapy. To achieve this goal, we will use a synthetic tool developed in our laboratoryto prepare enantiomerically enriched allenes through a selective C-N bond cleavage. This ERC-PoC will allow us to test the newchemical series as potential GPR40 agonists and to get insight into a SAR (Structure Activity Relationship) correlation with liver toxicityin order to compare the new molecules prepared in this proposal with those currently in clinical phase III trials.

Topics

Who is involved

OrganisationCityCountryRole
Universidad Autonoma De MadridMadridSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI